telmisartan + amlodipine + rosuvastatin placebo

This entity refers to a specific pharmaceutical intervention used as a comparator arm in clinical trials conducted by Jeil Pharmaceutical Co., Ltd., most notably the Phase III J-TAROS-RCT trial. It consists of a fixed-dose combination of the active antihypertensive agents telmisartan, an angiotensin II receptor blocker (ARB), and amlodipine, a calcium channel blocker (CCB), administered alongside a matching placebo for rosuvastatin. This formulation was designed to evaluate the efficacy and safety of adding rosuvastatin to a standard dual-therapy regimen in patients with concurrent hypertension and dyslipidemia. By maintaining the active components of the blood pressure-lowering therapy while substituting the lipid-lowering component with a placebo, researchers could isolate the therapeutic effects of the triple combination therapy (telmisartan/amlodipine/rosuvastatin) compared to dual therapy.

Other names

telmisartan + amlodipine + rosuvastatin placebo-Jeil Pharmaceutical Co., Ltd.-dyslipidemia-hypertensionGroup II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)